Healthscope

Who owns Healthscope?
Healthscope is owned by Brookfield Asset Management through Brookfield Business Partners, which acquired the company in June 2019 for A$4.4 billion. On May 26, 2025, the parent entities entered receivership, and McGrathNicol was appointed as receiver to oversee a sale of the business. Institutional partners including Caisse de depot et placement du Quebec (CDPQ) hold minority stakes.

Is Healthscope publicly traded?
No. Healthscope was delisted from the Australian Securities Exchange in June 2019 following Brookfield's acquisition. The company previously traded under stock codes HSP and HSO. It was also briefly delisted between 2010 and 2014 when it was owned by TPG Capital and The Carlyle Group.

What happened to Healthscope in 2025?
On May 26, 2025, Healthscope's parent entities (ANZ Hospitals Pty Ltd and Healthscope Newco Pty Ltd) entered receivership with approximately A$1.6 billion in debt. McGrathNicol was appointed as receiver, and KordaMentha was appointed as administrator. All 37 hospitals continue to operate normally. Commonwealth Bank provided A$100 million in emergency funding to support operations during the sale process.

How many hospitals does Healthscope operate?
Healthscope operates 37 private hospitals across every state and territory in Australia, including acute care, mental health, and rehabilitation facilities. Four hospitals have been sold to new operators: Gold Coast Private Hospital (to Mater), National Capital Private Hospital (to Ramsay Health Care), and Holmesglen and Hobart Private Hospitals (to Calvary Health Care). These transfers are subject to regulatory approvals.

Who is the CEO of Healthscope?
Tino La Spina is CEO of Healthscope and continues to lead the business during the receivership and sale process. He has stated that there is buyer interest in taking over the business as a whole, with 10 non-binding indicative offers received.

When will Healthscope be sold?
Receiver McGrathNicol has set a final deadline of July 21, 2026 for formal bids. Lenders are expected to examine competing bids and make a decision by early August 2026. A consortium led by Calvary, Pacific Equity Partners, and HMC Capital has been identified as a potential bidder for the remaining business.

Does Healthscope still operate pathology services?
No. Healthscope sold its Australian pathology business in 2015 and its New Zealand pathology business to NZ Super in August 2020. The company now focuses exclusively on hospital operations.

Healthscope was founded in 1985 as a private healthcare company focused on developing and operating private hospitals and medical centres across Australia. The company grew through acquisitions and organic expansion, establishing itself as one of Australia's leading private healthcare providers.

The company completed an initial public offering on the Australian Securities Exchange in 1994, raising A$70 million by issuing 40 million shares at A$1.75 each. Healthscope traded under the stock code HSP and later HSO, becoming part of the S&P/ASX 200 Index.

In October 2010, Healthscope was acquired by a consortium of funds advised and managed by TPG Capital and The Carlyle Group, and was subsequently delisted from the ASX. Following a period of growth under private ownership, the company was relisted on the ASX on July 28, 2014.

In January 2019, Brookfield Business Partners, a subsidiary of Canadian investment firm Brookfield Asset Management, announced an agreement to acquire Healthscope for approximately A$4.4 billion (US$4.1 billion). The acquisition was completed on June 6, 2019, through a scheme of arrangement. Brookfield partnered with institutional investors including Caisse de depot et placement du Quebec (CDPQ), which maintained a minority stake. The acquisition was funded with up to US$1.0 billion of equity, US$1.4 billion of long-term financing, and US$1.7 billion from the sale and long-term leaseback of 22 wholly-owned freehold hospital properties.

At the time of the Brookfield acquisition, Healthscope operated 43 private hospitals across Australia and 24 pathology laboratories across New Zealand. The company subsequently sold its New Zealand pathology business to NZ Super in August 2020 and divested its Australian pathology business earlier in 2015.

The Northern Beaches Hospital in Sydney, which opened during the acquisition process, experienced numerous operational problems, including staffing issues and emergency department failures. The hospital became a symbol of the challenges facing Healthscope under Brookfield ownership.

Healthscope accrued approximately A$1.6 billion in debt under Brookfield ownership and defaulted on various lease payments. In April 2024, lenders appointed McGrathNicol and Houlihan Lokey to help restructure the debt. After extended negotiations, lenders withdrew support and on May 26, 2025, appointed McGrathNicol as receivers to the parent entities. Commonwealth Bank of Australia provided A$100 million in emergency funding to support operations during the sale process, in addition to Healthscope's existing cash balance of A$110 million.

Healthscope's most significant controversy is the Northern Beaches Hospital in Sydney, which opened in 2018 with numerous operational problems including staffing shortages, emergency department failures, and patient safety concerns. The hospital became a symbol of the challenges facing Healthscope under Brookfield ownership and attracted significant media attention and regulatory scrutiny.

The receivership in May 2025 raised concerns about the continuity of essential healthcare services across 37 hospitals. Federal Health Minister Mark Butler publicly addressed the situation, stating that Healthscope had enough funds for several months of operations and that the government was monitoring the situation to ensure patient care was not disrupted.

The A$1.6 billion debt burden accumulated under Brookfield ownership has drawn criticism of private equity ownership models in healthcare. The sale and leaseback of 22 hospital properties at the time of the 2019 acquisition, which generated US$1.7 billion in financing, increased the company's lease obligations and reduced its financial flexibility.

The sale process has raised concerns about hospital closures, particularly in regional areas where Healthscope facilities may be the only private hospital option. McGrathNicol has stated its intention to transition all hospitals to new ownership with no plans for closures or redundancies.